WIRE)–InfraReDx, Inc., a medical device company committed to
advancing the diagnosis and management of coronary artery and other vascular
diseases, today announced the launch of its TVC Imaging System™, an enhanced
version of the LipiScan™ IVUS Coronary Imaging System. The TVC Imaging System
is a first-in-class intravascular imaging system that holds the potential to
revolutionize the management of coronary artery disease by providing
information that is critical for evaluating vessel structure and composition,
also known as true vessel characterization. The systems improved image
resolution delivers better clinical detail, providing more reliable vessel
interpretation and assessment. The device is the only multimodality imaging
system to combine both intravascular ultrasound (IVUS) and near-infrared
spectroscopy (NIRS). InfraReDx will debut the TVC Imaging System at the
upcoming annual Transcatheter Cardiovascular Therapeutics Meeting (TCT
2011), being held Nov. 7-11 in San
Francisco. The company will be exhibiting at booth
#807 during the conference.
“InfraReDx is committed to helping interventional
cardiologists deliver the best possible care for their patients by providing
intravascular imaging solutions that are easy to use and produce a more
complete view of the vessels structure and composition,” said Donald Southard,
president and chief executive officer of InfraReDx. “The TVC Imaging System
provides this additional information by combining high quality IVUS imaging
with InfraReDxs proprietary NIRS technology for compositional assessment. We
are pleased to announce that this next generation platform technology is now
available to customers in the U.S.
as well as in Europe.”
The imaging modalities used in interventional cardiology
today are limited in their ability to reveal comprehensive information
necessary to optimize clinical decision making and support treatment
strategies. The ability to visualize not only the physical structure of a
vessel, but also its composition and the potential presence of lipid core
plaque (LCP) of interest, enables interventional cardiologists to obtain true
vessel characterization and contributes to selection of optimal treatment for
patients. LCP is a fatty coronary artery plaque suspected to be vulnerable to
rupture, to cause most heart attacks and known to complicate stenting
procedures either during or following the placement of coronary artery stents.
The TVC Imaging System and its ability to detect LCP helps
interventional cardiologists identify which patients are at risk of stenting
complications, thereby facilitating the formulation of more precisely tailored
interventional treatment strategies. In a single pullback, the TVC Imaging
System provides rapid and automated detection of LCPs during the cardiac
catheterization procedure. Through IVUS technology, the TVC Imaging System
provides clear and relevant information about vessel structure in real time.
The systems NIRS technology enables interventional cardiologists to accurately
understand vessel composition and reliably visualize the presence of LCP that
are associated with plaque embolization and other complications of coronary
interventions. The multimodality images are obtained simultaneously and require
no post-processing or image manipulation. The TVC Imaging System is the only
device approved by the U.S. Food and Drug Administration for the detection of
About InfraReDx, Inc.
InfraReDx, Inc. is a privately-funded medical device company dedicated to
helping provide practitioners with the information needed for enhanced clinical
decision making in treating coronary artery disease. The company is committed
to improving the safety and efficacy of coronary stenting and ultimately
serving as part of a strategy to prevent initial coronary events. Through its
TVC Imaging System™, InfraReDx is changing the way coronary artery disease is
diagnosed and treated. The TVC Imaging System is the only intravascular imaging
system that enables true vessel characterization through simultaneous
structural and compositional imaging data obtained in a single pullback.
Through the use of both intravascular ultrasound (IVUS) and near-infrared
spectroscopy (NIRS) technologies, the system helps interventional cardiologists
identify which patients are prone to stenting complications by assessing not
only the degree of stenosis, but also the presence of lipid core plaque.
Founded in 1998, InfraReDx is headquartered in Burlington, Mass.
For more information, visit www.infraredx.com.